Evaluating Naxitamab for Refractory Ewing's Sarcoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the efficacy and safety of Naxitamab in patients with refractory Ewing's Sarcoma. It involves a prospective, interventional, open, randomized design across multiple centers in Poland. Patients will undergo biology screening to assess GD2 expression in their tumor samples, followed by randomization into experimental and control groups based on their GD2 status. The experimental group will receive a specific regimen of chemotherapy combined with Naxitamab, while the control group will receive standard treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Histologically proven Ewing sarcoma of the bone or soft tissues.
2. Subject's archival tumour sample (formalin-fixed, paraffin-embedded; FFPE) available for evaluation of GD2 expression.
3. Documented disease progression (during or after completion of at least one line treatment) or any subsequent recurrence.
4. GD2 positive tumor assessed by IHC.
5. Age ≥ 2 years and ≤ 21 years.
6. Life expectancy of at least 12 weeks from the time informed consent was signed.
7. Previous systemic anticancer treatment completed ≥ 3 weeks, major surgery ≥ 2 weeks, and radiation therapy ≥ 4 weeks prior to study enrollment.
8. Recovered from adverse effects of prior surgery, radiotherapy, or Clinical trial protocol BUTTERFLY version 1.0 of 30.09.2022 r.anti-neoplastic therapy at the discretion of the investigator.
9. Signing of informed consent for trial participation (including for naxitamab treatment) according with current legal regulations.
10. Consent to the use of effective contraception throughout the period of the study and a minimum of 1 year after discontinuation of study treatment in patients at puberty and sexual maturity

Exclusion Criteria:

1. Failure to meet any of the inclusion criteria.
2. Not eligible to IT.
3. Previous treatment with an anti-GD2 antibody.
4. Hypersensitivity to the study drugs or any of their ingredients (covers IT and naxitamab).
5. Simultaneous treatment with other drugs which might interact with naxitamab or IT regimen.
6. Persistent toxicity related to prior therapy, making it impossible to treat with naxitamab.
7. Significant cardiac conduction abnormalities, including known familial prolonged QT syndrome, or screening corrected QT interval (QTc) \>480 msec.
8. Symptoms of congestive heart failure or left ventricular ejection fraction \<50%.
9. Inadequate pulmonary function defined as evidence of dyspnea at rest, exercise intolerance, and/or chronic oxygen requirement. In addition, room air pulse oximetry \< 94% and/or abnormal pulmonary function tests if these assessments are clinically indicated.
10. Requirement, or likely requirement, for corticosteroids at doses \>10 mg prednisolone (or equivalent) per day or other immunosuppressive agents.
11. Diagnosis of other malignancies before study inclusion.
12. Planning to become pregnant (while being treated with IT or naxitamab), pregnancy or breastfeeding.
13. Other acute or persistent disorders, behaviors or abnormal laboratory test results, which might increase the risk related to the participation in this clinical trial or to taking the study drug, or which might influence the interpretation of the study results, or which, in the investigator's opinion, disqualify a patient from participating in the tri

Where it's running

• Mother and Child Institute
  Warsaw, Mazowian, Poland Recruiting
• Wroclaw Medical University
  Wroclaw, Poland Not yet recruiting

Study contacts

• Principal investigator: Anna Raciborska, Prof. — the Institue of Mother and Child
• Study coordinator: Anna Raciborska, Prof.
• Email: klinika.onkologii@imid.med.pl
• Phone: +48 22 32 77 205

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Dynamic ProGRP Changes During Ewing Sarcoma Treatment

  This study tests whether changes in serum ProGRP levels over time reflect how well newly diagnosed Ewing sarcoma responds to treatment.

  Recruiting Peking University People's Hospital · Beijing · NCT07725783

• Methionine-Reduced Diet in Solid Tumors (early-phase)

  A small pilot study will test whether a methionine-reduced diet can change blood levels in adults with various solid tumors who are receiving standard cancer therapy.

  Recruiting Early Phase 1 University of California, Irvine · Orange, California · NCT07628634

• Naxitamab added to standard induction therapy for newly diagnosed high-risk neuroblastoma

  This study tests whether adding Naxitamab and GM-CSF to the standard induction therapy improves outcomes for children and young people with newly diagnosed high-risk neuroblastoma.

  Recruiting Phase 2 Shaare Zedek Medical Center · Jerusalem · NCT07537400

• Adaptive Proton Therapy for Pediatric Solid Tumors and Hodgkin Lymphoma

  This study tests a regular imaging approach to see if proton therapy plans for children with solid tumors or Hodgkin lymphoma should be updated during treatment.

  Recruiting St. Jude Children's Research Hospital · Memphis, Tennessee · NCT07514819

• Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma

  This trial tests whether adding eflornithine (DFMO) as extra or maintenance therapy can improve survival for young people with Ewing sarcoma or osteosarcoma.

  Recruiting at 3 sites Phase 2 Milton S. Hershey Medical Center · Tampa, Florida and 2 other locations · NCT07321912

• Xaluritamig for relapsed or refractory Ewing sarcoma in adults, adolescents, and children

  This trial will test xaluritamig in adults, adolescents, and children with relapsed or refractory Ewing sarcoma to find a recommended dose for expansion and check safety and tolerability.

  Recruiting at 13 sites Phase 1 Amgen · Los Angeles, California and 12 other locations · NCT07297979

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.